摘要
目的:比较在e抗原阳性慢性乙型肝炎患者中应用替比夫定与拉米夫定的效果差异。方法:选择HBe Ag阳性CHB患者112例,随机分为替比夫定组(56例)和拉米夫定组(56例)给予替比夫定和拉米夫定治疗。比较两间HBe Ag转阴率、HBV DNA转阴率、ALT复常率、HBe Ag血清学转换率以及不良反应发生率。结果:替比夫定组ALT复常率明显高于拉米夫定组(P<0.05)。前12周,两组HBe Ag转阴率、DNA转阴率和HBe Ag血清学转换率比较差异无统计学意义(P>0.05);12周后,替比夫定组HBe Ag转阴率和HBV DNA转阴率明显高于拉米夫定组(P<0.05);替比夫定组的不良反应率显著低于拉米夫定(P<0.05)。结论:在e抗原阳性CHB患者中应用替比夫定,具有较高的HBe Ag转阴率、DNA转阴率、ALT复常率,在24周以后更为明显,且不良反应率更低。
Objective： To compare the clinical effect of telbivudine and lamivudine on patients with HBe Agpositive CHB. Methods： 112 patients with HBe Ag-positive CHB were randomized into the telbivudine treatment group and lamivudine treatment group,with 56 cases in each group. The negative conversion rate of Hbe Ag and HBV DNA,ALT normalization rate,HBe Ag serology conversion rate and rate of adverse events for both groups was compared. Results： The ALT normalization rate for telbivudine treatment group was significantly higher than that of lamivudine treatment group（ P〈0. 05）; in the first 12 weeks of treatment,the negative conversion rate of Hbe Ag and DNA,and HBe Ag serology conversion rate for both groups was not significantly different（ P〉0.05）,but after 12 weeks of treatment,the negative conversion rate of HBe Ag and HBV DNA for the telbivudine treatment group was significantly higher than that of the lamivudine treatment group（ P〈0.05）; the rate of adverse events for the telbivudine treatment group was significantly lower than that of the lamivudine group（ P〈0.05）. Conclusion： For patients with HBe Agpositive CHB,telbivudine can improve the negative conversion rate of Hbe Ag and DNA, and ALT normalization rate,and reduce the rate of adverse events. After 24 weeks of treatment,the clinical effect is more obvious and the adverse events are even lower.
出处
《华夏医学》
CAS
2017年第4期14-17,共4页
Acta Medicinae Sinica
